ARGX vs. MEDP: argenx vs. Medpace Stock Comparison

Company Profile

argenx (ARGX) and Medpace (MEDP) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ARGX is classified in Biotechnology while MEDP is classified in Life Sciences Tools & Services.

Medpace (MEDP) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Medpace (MEDP) earns 117.88% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.

Both argenx (ARGX) at 31.73% and Medpace (MEDP) at 18.24% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both argenx (ARGX) at 36.27% and Medpace (MEDP) at 23.12% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Medpace (MEDP) at 19.97% is closer to the peer norm — faster top-line expansion for ARGX.

Both argenx (ARGX) at 53.13% and Medpace (MEDP) at 20.98% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Medpace (MEDP) shows current ratio of 0.83 against its industry benchmark, while argenx (ARGX) has no reading this period.

argenx (ARGX) at 0.01 keeps leverage in the lower industry quartile, while Medpace (MEDP) at 0.29 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Neither argenx (ARGX) nor Medpace (MEDP) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither argenx (ARGX) nor Medpace (MEDP) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Both argenx (ARGX) at 32.12 and Medpace (MEDP) at 36.26 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

On P/S ratio, both argenx (ARGX) at 9.86 and Medpace (MEDP) at 6.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Measured against book value, both argenx (ARGX) at 172.23 and Medpace (MEDP) at 31.23 look expensive — each P/B ratio sits above its industry’s benchmark range.

Valuation Metrics